Down But Not Out, Ranbaxy Eyes Generics Blockbuster Launches In China
This article was originally published in PharmAsia News
Executive Summary
Fierce competition makes China a tough nut to crack for generics, something India’s largest drug manufacturer Ranbaxy says it has learned the hard way, but after walking away from a joint venture, the firm is ready to try again.
You may also be interested in...
Slow Growth And Tough Market Make China An Intriguing Puzzle For Indian Companies
MUMBAI - For large Indian drug companies, China has been a traditional and, to an extent, a dreaded rival in the business of pharmaceutical raw materials. Gargantuan Chinese factories that cropped up in the eighties almost killed scores of Indian bulk drug manufacturing units as every pricing strategy the Indian outfits could conceive of failed to beat the quotations offered by Chinese manufacturers to global brand name companies
China May Ease Data Transfer Rules But Regulatory Ambiguity Remains
China's latest proposed rules governing the overseas transfer of personal data may allow pharma, biotech and digital health companies to avoid regulatory security reviews and formal standard contracts, as well as personal information protection certification, but key definitions of “important data” and “negative list” items remain to be clarified.
Hengrui, Affiliate Reistone In Apparent Dispute Over China Ivarmacitinib NDAs
The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.